|
|
|
|
| LEADER |
00000cam a2200000Mu 4500 |
| 001 |
on1152063539 |
| 003 |
OCoLC |
| 005 |
20240809213013.0 |
| 006 |
m d |
| 007 |
cr ||||||||||| |
| 008 |
200425s2020 xx o ||| 0 eng d |
| 040 |
|
|
|a EBLCP
|b eng
|c EBLCP
|d YDX
|d UKMGB
|d OCLCO
|d OCLCF
|d OCLCO
|d OCLCQ
|d OCLCO
|d OCLCQ
|d REDDC
|d OCLCL
|d UEJ
|
| 015 |
|
|
|a GBB9K4825
|2 bnb
|
| 016 |
7 |
|
|a 019654924
|2 Uk
|
| 019 |
|
|
|a 1152353392
|a 1153202450
|
| 020 |
|
|
|a 9781351718660
|
| 020 |
|
|
|a 1351718665
|
| 020 |
|
|
|z 113874848X
|
| 020 |
|
|
|z 9781138748484
|
| 020 |
|
|
|a 9781351718677
|q (PDF ebook)
|
| 020 |
|
|
|a 1351718673
|
| 020 |
|
|
|a 9781351718653
|q (Mobipocket ebook)
|
| 020 |
|
|
|a 1351718657
|
| 020 |
|
|
|a 9781315180212
|q (ebook)
|
| 020 |
|
|
|a 1315180219
|
| 024 |
8 |
|
|a 10.1201/9781315180212
|2 doi
|
| 035 |
|
|
|a (OCoLC)1152063539
|z (OCoLC)1152353392
|z (OCoLC)1153202450
|
| 037 |
|
|
|a 9781351718660
|b Ingram Content Group
|
| 050 |
|
4 |
|a R853.C55
|b .B394 2020
|
| 049 |
|
|
|a HCDD
|
| 100 |
1 |
|
|a Lesaffre, Emmanuel.
|
| 245 |
1 |
0 |
|a Bayesian Methods in Pharmaceutical Research
|h [electronic resource].
|
| 260 |
|
|
|a Milton :
|b CRC Press LLC,
|c 2020.
|
| 300 |
|
|
|a 1 online resource (547 p.).
|
| 336 |
|
|
|a text
|2 rdacontent
|
| 336 |
|
|
|a still image
|2 rdacontent
|
| 337 |
|
|
|a computer
|2 rdamedia
|
| 338 |
|
|
|a online resource
|2 rdacarrier
|
| 490 |
1 |
|
|a Chapman and Hall/CRC Biostatistics Ser.
|
| 500 |
|
|
|a Description based upon print version of record.
|
| 505 |
0 |
|
|a Cover -- Half Title -- Series Page -- Title Page -- Copyright Page -- Dedication -- Contents -- Preface -- Editors -- Contributors -- List of abbreviations -- Part I: Introduction -- 1. Bayesian Background -- 1.1 Introduction -- 1.2 The frequentist approach to inference -- 1.3 Bayesian concepts -- 1.4 More than one parameter -- 1.5 Choosing the prior distribution -- 1.6 Determining the posterior distribution numerically -- 1.7 Hierarchical models and data augmentation -- 1.8 Model selection and model checking -- 1.9 Bayesian nonparametric methods -- 1.10 Bayesian software
|
| 505 |
8 |
|
|a 1.11 Further reading -- 2. FDA Regulatory Acceptance of Bayesian Statistics -- 2.1 Introduction -- 2.2 Medical devices -- 2.3 Pharmaceutical products -- 2.4 Differences between devices and drugs -- 2.5 Some promising opportunities in pharmaceutical drugs -- 2.6 The future -- 2.7 Conclusion -- 3. Bayesian Tail Probabilities for Decision Making -- 3.1 Introduction -- 3.2 Posterior tail probabilities -- 3.3 Predictive tail probabilities -- 3.4 Discussion -- Part II: Clinical development -- 4. Clinical Development in the Light of Bayesian Statistics -- 4.1 Introduction
|
| 505 |
8 |
|
|a 4.2 Introduction to drug development -- 4.3 Quantitative decision making in drug development -- 4.4 Bayesian thinking -- 4.5 Applications of Bayesian methods in drug development -- 4.6 Conclusion -- 5. Prior Elicitation -- 5.1 Introduction -- 5.2 Methods for prior elicitation -- 5.3 Examples -- 5.4 Impact and outlook -- 6. Use of Historical Data -- 6.1 Introduction -- 6.2 Identifying historical or co-data -- 6.3 An example: Guillain-Barré syndrome in children -- 6.4 Methods -- 6.5 Application: Non-inferiority trials -- 6.6 Discussion -- 6.7 Code -- 7. Dose Ranging Studies and Dose Determination
|
| 505 |
8 |
|
|a 7.1 Introduction -- 7.2 Dose-response studies -- 7.3 Dose escalation trials in oncology -- 7.4 Conclusions -- 8. Bayesian Adaptive Designs in Drug Development -- 8.1 Introduction -- 8.2 Brief history of adaptive designs -- 8.3 What is an adaptive clinical trial? -- 8.4 Types of adaptation -- 8.5 Reasons we might consider adaptive designs -- 8.6 Example of an adaptive design -- 8.7 Adaptive enrichment designs -- 8.8 Some criticisms of adaptive designs -- 8.9 Summary -- 9. Bayesian Methods for Longitudinal Data with Missingness -- 9.1 Introduction -- 9.2 Common frequentist approaches
|
| 505 |
8 |
|
|a 9.3 Bayesian approaches -- 9.4 Ignorable and nonignorable missingness -- 9.5 Posterior inference -- 9.6 Model selection -- 9.7 Model checking and assessment -- 9.8 Practical example: Growth hormone trial -- 9.9 Wrap-up and open problems -- 10. Survival Analysis and Censored Data -- 10.1 Introduction -- 10.2 Review of survival analysis -- 10.3 Software -- 10.4 Applications -- 10.5 Reporting -- 10.6 Other comments -- 11. Benefit of Bayesian Clustering of Longitudinal Data: Study of Cognitive Decline for Precision Medicine -- 11.1 Introduction -- 11.2 Motivating example
|
| 500 |
|
|
|a 11.3 Nonparametric Bayesian models
|
| 650 |
|
0 |
|a Pharmacy
|x Research
|x Statistical methods.
|
| 650 |
|
0 |
|a Bayesian statistical decision theory.
|
| 650 |
|
7 |
|a Bayesian statistical decision theory
|2 fast
|
| 650 |
|
7 |
|a Pharmacy
|x Research
|x Statistical methods
|2 fast
|
| 700 |
1 |
|
|a Baio, Gianluca.
|
| 700 |
1 |
|
|a Boulanger, Bruno.
|
| 758 |
|
|
|i has work:
|a Bayesian methods in pharmaceutical research (Text)
|1 https://id.oclc.org/worldcat/entity/E39PCGWKk6M9Ktrjp8XW6gdrmb
|4 https://id.oclc.org/worldcat/ontology/hasWork
|
| 776 |
0 |
8 |
|i Print version:
|a Lesaffre, Emmanuel
|t Bayesian Methods in Pharmaceutical Research
|d Milton : CRC Press LLC,c2020
|z 9781138748484
|
| 830 |
|
0 |
|a Chapman and Hall/CRC Biostatistics Ser.
|
| 856 |
4 |
0 |
|u https://ebookcentral.proquest.com/lib/holycrosscollege-ebooks/detail.action?docID=6181239
|y Click for online access
|
| 903 |
|
|
|a EBC-AC
|
| 994 |
|
|
|a 92
|b HCD
|